Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

POD Primer: Some Physician-Owned Device Distributors Can Pass Muster

This article was originally published in The Gray Sheet

Executive Summary

The best physician-owned distributors “do not bill Medicare at all,” POD-supporter Truhe said at a May 21 meeting. Instead, the distributors can sell a variety of implantable devices to hospitals, without steering the hospital to buy just one manufacturer’s wares.

You may also be interested in...



PODs Alert: HHS Inspector General Issues Fraud Warning For Physician-Owned Device Distributors

The March 26 special fraud alert reiterates the HHS watchdog’s “longstanding position that the opportunity for a referring physician to earn a profit, including through an investment in an entity for which he or she generates business, could constitute illegal remuneration under the anti-kickback statute.”

Senators Seek Scrutiny Of Physician-Owned Device Distributors

Five senior senators are urging the Health and Human Services Office of Inspector General to investigate the proliferation of entities that can steer surgeons to make implant choices based on personal profit.

Biocon Eyes 'Foothold To Stronghold' For (b)Humira In US, Pauses RH-Insulin Program

Biocon sees some wins for biosimilar adalimumab in the US and signals more opportunities amid the slower than anticipated build-out for Humira rivals. Chinese competition looms for glargine, but the Indian company declares it “will be competitive if these folks launch.”

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031257

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel